Biocon arm gets UK MHRA marketing authorisation for ophthalmic drug Yesafili Ruchika Sharma14 Nov 2023 5:59 AMIt is highly similar to the reference product Eylea (aflibercept).
Biocon Biologics gets European Commission nod for critical eye treatment medicine Yesafili Ruchika Sharma21 Sept 2023 8:00 AMBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced that the European Commission (EC) has granted marketing authorization in...
Submit interim analysis results of study in Russia and India: CDSCO panel Tells Lupin Over Aflibercept Dr. Divya Colin28 Aug 2023 12:30 PMNew Delhi: In response to the proposal to enroll an additional 298 patients from India in the study of the ophthalmic drug Aflibercept, the Subject...
Regeneron Pharma Eylea HD injection approved by USFDA for treatment of Wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy Ruchika Sharma21 Aug 2023 8:00 AMTarrytown: Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD...
Regeneron Pharma secures USFDA okay for Veopoz for children, adults with Chaple disease Ruchika Sharma19 Aug 2023 6:10 AMVeopoz, a fully human monoclonal antibody, is designed to target complement factor C5, a protein involved in complement system activation.
Sandoz releases positive results from Mylight Phase lll study for biosimilar Aflibercept Ruchika Sharma16 Aug 2023 9:30 AMAflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor A and placental growth factor (PlGF), inhibiting abnormal...
Biocon Biologics gets EMA Committee positive opinion for Yesafili Ruchika Sharma25 July 2023 12:00 PMIt is highly similar to the reference product Eylea (aflibercept).
Zydus Lifescience Gets CDSCO Panel Nod to Study Aflibercept Dr. Divya Colin7 Jun 2023 12:30 PMNew Delhi: The drug major Zydus Lifescience has got the green signal from the Subject Expert Committee SEC functional under Central Drug Standard...
First-line bevacizumab treatment cost-effective for CRVO or HRVO-associated macular oedema: JAMA Medha Baranwal23 May 2023 5:00 AMUSA: First-line treatment with bevacizumab of macular oedema associated with central or hemiretinal vein occlusion was cost-effective in a new...
Bayer submits Aflibercept 8 mg for regulatory approval in two major retinal eye diseases in EU Ruchika Sharma7 Feb 2023 8:45 AMAflibercept 8 mg is being jointly developed by Bayer and Regeneron.
Aflibercept outperforms bevacizumab for weaning off at one year among wet AMD patients Dr. Kamal Kant Kohli1 Dec 2022 2:30 PMResearchers at Wilmer Eye Institute at Johns Hopkins Medicine have found in a new study that nearly half of patients of age-related macular...
Regeneron gets six months of US pediatric exclusivity for Eylea injection Ruchika Sharma23 Oct 2022 10:00 AMEYLEA is a VEGF inhibitor formulated as an injection for the eye
